Vizual Stocks works best vertically on mobile.
VizualStocks APIOperating KPI and segment definitions available for GSK (GSK) through the VizualStocks API.
Sales of Arexvy, GSK’s vaccine against respiratory syncytial virus. The series begins after commercial launch and measures sales rather than vaccinations.
arexvyRevenueSales reported by GSK under Cabenuva, the long-acting injectable HIV treatment combining cabotegravir and rilpivirine. These sales are included in ViiV Healthcare’s HIV franchise total.
cabenuvaRevenueSales of Dovato, ViiV Healthcare’s two-drug oral HIV treatment combining dolutegravir and lamivudine. These sales are included in the HIV franchise total.
dovatoRevenueGSK continuing-operations sales allocated to Europe, including the United Kingdom, in its quarterly geographic sales tables. This series excludes the Consumer Healthcare business separated as Haleon.
europeRevenueSales from GSK’s established respiratory and other general medicines, including Trelegy, Anoro, Augmentin and other mature brands. This product-area total includes reported contract manufacturing revenue and uses the reporting structure introduced in 2022.
generalMedicinesRevenueSales of GSK’s HIV treatment and prevention medicines through ViiV Healthcare, including oral regimens and long-acting injectables. The franchise total includes products beyond the separately tracked Dovato and Cabenuva brands.
hivRevenueGSK continuing-operations sales allocated to markets outside the United States and Europe in its geographic sales tables. This series excludes the Consumer Healthcare business separated as Haleon.
internationalRevenueSales of Nucala (mepolizumab), GSK’s anti-IL-5 biologic used for severe asthma and other approved eosinophilic conditions, including COPD where approved. These sales form part of the specialty respiratory and immunology portfolio.
nucalaRevenueSales of GSK’s cancer medicines grouped in its Oncology franchise, including Zejula, Jemperli and Ojjaara/Omjjara where marketed. The product portfolio changes as medicines are acquired, launched or withdrawn.
oncologyRevenueSales of specialty medicines in GSK’s Respiratory, Immunology & Inflammation franchise, including Nucala and Benlysta. This series begins with that named presentation and excludes general respiratory medicines such as Trelegy.
respiratoryImmunologyInflammationRevenueSales of Shingrix, GSK’s recombinant adjuvanted vaccine against shingles. The series measures product sales rather than doses administered.
shingrixRevenueSales of GSK’s specialty medicines, including HIV, oncology and immune-system treatments. This product-area disaggregation includes pandemic medicines where reported and uses the reporting structure introduced in 2022.
specialtyMedicinesRevenueSales of Trelegy Ellipta, GSK’s inhaled triple combination of fluticasone furoate, umeclidinium and vilanterol for COPD and asthma. These sales are included within General Medicines under the current reporting structure.
trelegyRevenueGSK continuing-operations sales allocated to the United States in its geographic sales tables. This series excludes the Consumer Healthcare business separated as Haleon.
usRevenueSales of GSK’s vaccines for shingles, meningitis, respiratory syncytial virus, influenza and other infectious diseases. This is the Vaccines product-area total, including established paediatric and adult vaccines.
vaccinesRevenue